Ricardo Gonzales, MD
Neurology · Sarasota, FLNPI 1063678035
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,460 of the $96,971 with a category attached, or 84.0%. Teva Pharmaceuticals USA, Inc. accounts for 89.6% of it on its own, with 48 other manufacturers making up the rest. 2025 is the largest year on record at $31,233, 3.0 times the $10,267 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 662 payments — averaging $146.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$87K
- AbbVie$2K
- Abbott$624
- Pfizer$576
- Amgen$560
- Novartis$528
- plus $6K from 43 others
Across 2 payments — averaging $4600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$9K
What the payments were for
- Consulting fees$6101%
- Speaking & faculty fees$81,46084%
- Travel & lodging$1,2891%
- Food & beverage$13,55014%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$96,971 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 45 | $265,065 |
| AustedoDeutetrabenazine | 33 | $242,118 |
| NuplazidPimavanserin Tartrate | 42 | $228,269 |
| RytaryCarbidopa/Levodopa | 84 | $145,591 |
| GocovriAmantadine Hcl | 39 | $123,562 |
| NeuproRotigotine | 59 | $74,080 |
| InbrijaLevodopa | 19 | $73,974 |
| Rasagiline Mesylate | 328 | $53,224 |
| Nurtec OdtRimegepant Sulfate | 25 | $24,795 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $20,171 |
| Emgality PenGalcanezumab-Gnlm | 23 | $19,055 |
| UbrelvyUbrogepant | 14 | $16,075 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 749 | $13,983 |
| BotoxOnabotulinumtoxina | 11 | $11,896 |
| Memantine Hcl | 260 | $10,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $86,927 | $507,18378 claims |
| Acadia Pharmaceuticals IncNuplazid | $184 | $228,26942 claims |
| Amneal Pharmaceuticals LLCRytary | $163 | $145,59184 claims |
| MDD US Operations, LLCGocovri | $414 | $123,56239 claims |
| UCB, Inc.Neupro | $449 | $74,08059 claims |
| Acorda Therapeutics, IncInbrija | $517 | $73,97419 claims |
| AbbVieUbrelvy, Botox | $1,789 | $27,97125 claims |
| PfizerNurtec Odt | $576 | $24,79525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Sarasota
- Donald NegroskiSarasota$1.4M
- Julio CanteroSarasota$811K
- Victor KassiciehSarasota$318K
- Gregory HanesSarasota$255K
- Maurico ConchaSarasota$212K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.